Patents by Inventor Michael Rynkiewicz

Michael Rynkiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized anti-EGFR antibody L4-H3 and coding gene thereof
    Patent number: 9028832
    Abstract: A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: May 12, 2015
    Assignee: HeFei Tairui Biotechnology Co., Ltd.
    Inventors: Yanwen Jin, David Weaver, Michael Rynkiewicz, Cheng Cao
  • Anti-epidermal growth factor receptor antibodies and uses thereof
    Patent number: 8653244
    Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10?10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: February 18, 2014
    Assignee: Guangzhou Yunyuan Biotech Co., Ltd.
    Inventors: David Weaver, Michael Rynkiewicz, Cheng Cao, Yanwen Jin
  • HUMANIZED ANTI-EGFR ANTIBODY L4-H3 AND CODING GENE THEREOF
    Publication number: 20130330362
    Abstract: A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.
    Type: Application
    Filed: March 25, 2011
    Publication date: December 12, 2013
    Applicant: HEFEI TAIRUI BIOTECHNOLOGY CO., LTD
    Inventors: Yanwen Jin, David Weaver, Michael Rynkiewicz, Cheng Cao
  • Anti-epidermal growth factor receptor antibodies and uses thereof
    Patent number: 8486895
    Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10?10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: July 16, 2013
    Assignee: Guangzhou Yunyuan Biotech Co., Ltd.
    Inventors: David Weaver, Michael Rynkiewicz, Cheng Cao, Yanwen Jin
  • ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF
    Publication number: 20130022624
    Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10?10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
    Type: Application
    Filed: December 30, 2009
    Publication date: January 24, 2013
    Applicant: Guangzhou Recomgen Biotech Co., Ltd.
    Inventors: David Weaver, Michael Rynkiewicz, Cheng Cao, Yanwen Jin
  • Methods for humanizing antibodies and humanized antibodies made thereby
    Patent number: 8343489
    Abstract: Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: January 1, 2013
    Inventors: David T. Weaver, Michael Rynkiewicz
  • ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF
    Publication number: 20120321643
    Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10?10 mol/L) and are able to inhibit the growth and migration of tumor cells.
    Type: Application
    Filed: December 30, 2009
    Publication date: December 20, 2012
    Applicant: GUANGZHOU RECOMGEN BIOTECH CO., LTD.
    Inventors: David Weaver, Michael Rynkiewicz, Cheng Cao, Yanwen Jin
  • METHODS FOR HUMANIZING ANTIBODIES AND HUMANIZED ANTIBODIES MADE THEREBY
    Publication number: 20090130102
    Abstract: Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.
    Type: Application
    Filed: March 21, 2007
    Publication date: May 21, 2009
    Inventors: David T. Weaver, Michael Rynkiewicz
  • Substituted azetidinones
    Publication number: 20070105832
    Abstract: Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd? are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.
    Type: Application
    Filed: April 4, 2006
    Publication date: May 10, 2007
    Inventors: Thomas Bannister, Cassandra Celatka, Nizal Chandrakumar, Hongfeng Deng, Zihong Guo, Lei Jin, Tsvetelina Lazarova, Jian Lin, Scott Moe, Pamela Nagafuji, Manuel Navia, Amy Ripka, Michael Rynkiewicz, Kerry Spear, James Stickler, Roger Xie
  • Compounds and methods for treatment of thrombosis
    Publication number: 20050143317
    Abstract: The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
    Type: Application
    Filed: April 2, 2004
    Publication date: June 30, 2005
    Inventors: Sherin Abdel-Meguid, Robert Babine, Hongfeng Deng, Lei Jin, Jian Lin, Scott Magee, Harold Meyers, Pramod Pandey, Michael Rynkiewicz, David Weaver, Zihong Gho, Thomas Bannister